Calcitonin use in giant cell bone tumors
Summary Introduction As osteoclast, giant cell tumors express calcitonin receptors. The aim of this paper is to assess treatment using salmon calcitonin after curettage. Material and methods We retrospectively reviewed 25 patients with giant cell tumor of the appendicular skeleton treated with a sin...
Gespeichert in:
| Veröffentlicht in: | Orthopaedics & traumatology, surgery & research surgery & research, 2011-09, Vol.97 (5), p.520-526 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 526 |
|---|---|
| container_issue | 5 |
| container_start_page | 520 |
| container_title | Orthopaedics & traumatology, surgery & research |
| container_volume | 97 |
| creator | Nouri, H Hedi Meherzi, M Ouertatani, M Mestiri, M Zehi, K Douik, M Zouari, M |
| description | Summary Introduction As osteoclast, giant cell tumors express calcitonin receptors. The aim of this paper is to assess treatment using salmon calcitonin after curettage. Material and methods We retrospectively reviewed 25 patients with giant cell tumor of the appendicular skeleton treated with a single protocol of calcitonin administration following curettage in order to assess the effectiveness of calcitonin in reducing the rate of local recurrence. Results The mean duration follow-up was 68 months. Thirteen patients (52%) had local recurrence. Eight of them were treated successfully after repeated curettage and calcitonin. Four patients had bone resection and one patient had curettage and cement filling. All patients with cavity left empty had ossified and the functional score as assessed by the MSTS score was 28.02/30. Conclusion This study suggests that the use of calcitonin as adjuvant is not effective and that filling agents are not required after curettage of giant cell tumors. Level of evidence Level 4. |
| doi_str_mv | 10.1016/j.otsr.2011.03.019 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_887503575</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S1877056811001277</els_id><sourcerecordid>887503575</sourcerecordid><originalsourceid>FETCH-LOGICAL-c454t-d11051e10e147a59d76baf9458d26a81160b2021c9e173e718ee06527a57e49e3</originalsourceid><addsrcrecordid>eNp9kU1LxDAQhoMouq7-AQ_Sm162zqRN04IIsvgFggf1HNJ0VrJ2G01awX9vyq4iHjzNHJ73JXmGsSOEFAGLs2Xq-uBTDogpZClgtcUmWEo5A1GU27_2PbYfwhKgKDDju2yPo-QZRzFhp3PdGtu7znbJECiJ48Xqrk8MtW1Su46Sflg5Hw7YzkK3gQ43c8qer6-e5rez-4ebu_nl_czkIu9nDSIIJATCXGpRNbKo9aLKRdnwQpeIBdQcOJqKUGYksSSCQvDISsoryqbsZN375t37QKFXKxvGx-iO3BBUWUoBmZAiknxNGu9C8LRQb96utP9UCGoUpJZqFKRGQQoyFQXF0PGmfqhX1PxEvo1E4HwNUPzkhyWvgrHUGWqsJ9Orxtn_-y_-xE1rO2t0-0qfFJZu8F3Up1AFrkA9jicaLxS1AXIpsy-JZolU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>887503575</pqid></control><display><type>article</type><title>Calcitonin use in giant cell bone tumors</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Nouri, H ; Hedi Meherzi, M ; Ouertatani, M ; Mestiri, M ; Zehi, K ; Douik, M ; Zouari, M</creator><creatorcontrib>Nouri, H ; Hedi Meherzi, M ; Ouertatani, M ; Mestiri, M ; Zehi, K ; Douik, M ; Zouari, M</creatorcontrib><description>Summary Introduction As osteoclast, giant cell tumors express calcitonin receptors. The aim of this paper is to assess treatment using salmon calcitonin after curettage. Material and methods We retrospectively reviewed 25 patients with giant cell tumor of the appendicular skeleton treated with a single protocol of calcitonin administration following curettage in order to assess the effectiveness of calcitonin in reducing the rate of local recurrence. Results The mean duration follow-up was 68 months. Thirteen patients (52%) had local recurrence. Eight of them were treated successfully after repeated curettage and calcitonin. Four patients had bone resection and one patient had curettage and cement filling. All patients with cavity left empty had ossified and the functional score as assessed by the MSTS score was 28.02/30. Conclusion This study suggests that the use of calcitonin as adjuvant is not effective and that filling agents are not required after curettage of giant cell tumors. Level of evidence Level 4.</description><identifier>ISSN: 1877-0568</identifier><identifier>EISSN: 1877-0568</identifier><identifier>DOI: 10.1016/j.otsr.2011.03.019</identifier><identifier>PMID: 21723215</identifier><language>eng</language><publisher>France: Elsevier Masson SAS</publisher><subject>Adolescent ; Adult ; Aged ; Bone ; Bone Density Conservation Agents - therapeutic use ; Bone Neoplasms - prevention & control ; Bone Neoplasms - surgery ; Calcitonin ; Calcitonin - therapeutic use ; Chemotherapy, Adjuvant ; Curettage ; Female ; Giant cell tumor ; Giant Cell Tumor of Bone - prevention & control ; Giant Cell Tumor of Bone - surgery ; Humans ; Male ; Middle Aged ; Neoplasm Recurrence, Local - prevention & control ; Orthopedics ; Retrospective Studies ; Surgery ; Young Adult</subject><ispartof>Orthopaedics & traumatology, surgery & research, 2011-09, Vol.97 (5), p.520-526</ispartof><rights>2011</rights><rights>Copyright © 2011. Published by Elsevier Masson SAS.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c454t-d11051e10e147a59d76baf9458d26a81160b2021c9e173e718ee06527a57e49e3</citedby><cites>FETCH-LOGICAL-c454t-d11051e10e147a59d76baf9458d26a81160b2021c9e173e718ee06527a57e49e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.otsr.2011.03.019$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,3548,27923,27924,45994</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21723215$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nouri, H</creatorcontrib><creatorcontrib>Hedi Meherzi, M</creatorcontrib><creatorcontrib>Ouertatani, M</creatorcontrib><creatorcontrib>Mestiri, M</creatorcontrib><creatorcontrib>Zehi, K</creatorcontrib><creatorcontrib>Douik, M</creatorcontrib><creatorcontrib>Zouari, M</creatorcontrib><title>Calcitonin use in giant cell bone tumors</title><title>Orthopaedics & traumatology, surgery & research</title><addtitle>Orthop Traumatol Surg Res</addtitle><description>Summary Introduction As osteoclast, giant cell tumors express calcitonin receptors. The aim of this paper is to assess treatment using salmon calcitonin after curettage. Material and methods We retrospectively reviewed 25 patients with giant cell tumor of the appendicular skeleton treated with a single protocol of calcitonin administration following curettage in order to assess the effectiveness of calcitonin in reducing the rate of local recurrence. Results The mean duration follow-up was 68 months. Thirteen patients (52%) had local recurrence. Eight of them were treated successfully after repeated curettage and calcitonin. Four patients had bone resection and one patient had curettage and cement filling. All patients with cavity left empty had ossified and the functional score as assessed by the MSTS score was 28.02/30. Conclusion This study suggests that the use of calcitonin as adjuvant is not effective and that filling agents are not required after curettage of giant cell tumors. Level of evidence Level 4.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Bone</subject><subject>Bone Density Conservation Agents - therapeutic use</subject><subject>Bone Neoplasms - prevention & control</subject><subject>Bone Neoplasms - surgery</subject><subject>Calcitonin</subject><subject>Calcitonin - therapeutic use</subject><subject>Chemotherapy, Adjuvant</subject><subject>Curettage</subject><subject>Female</subject><subject>Giant cell tumor</subject><subject>Giant Cell Tumor of Bone - prevention & control</subject><subject>Giant Cell Tumor of Bone - surgery</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neoplasm Recurrence, Local - prevention & control</subject><subject>Orthopedics</subject><subject>Retrospective Studies</subject><subject>Surgery</subject><subject>Young Adult</subject><issn>1877-0568</issn><issn>1877-0568</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kU1LxDAQhoMouq7-AQ_Sm162zqRN04IIsvgFggf1HNJ0VrJ2G01awX9vyq4iHjzNHJ73JXmGsSOEFAGLs2Xq-uBTDogpZClgtcUmWEo5A1GU27_2PbYfwhKgKDDju2yPo-QZRzFhp3PdGtu7znbJECiJ48Xqrk8MtW1Su46Sflg5Hw7YzkK3gQ43c8qer6-e5rez-4ebu_nl_czkIu9nDSIIJATCXGpRNbKo9aLKRdnwQpeIBdQcOJqKUGYksSSCQvDISsoryqbsZN375t37QKFXKxvGx-iO3BBUWUoBmZAiknxNGu9C8LRQb96utP9UCGoUpJZqFKRGQQoyFQXF0PGmfqhX1PxEvo1E4HwNUPzkhyWvgrHUGWqsJ9Orxtn_-y_-xE1rO2t0-0qfFJZu8F3Up1AFrkA9jicaLxS1AXIpsy-JZolU</recordid><startdate>20110901</startdate><enddate>20110901</enddate><creator>Nouri, H</creator><creator>Hedi Meherzi, M</creator><creator>Ouertatani, M</creator><creator>Mestiri, M</creator><creator>Zehi, K</creator><creator>Douik, M</creator><creator>Zouari, M</creator><general>Elsevier Masson SAS</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20110901</creationdate><title>Calcitonin use in giant cell bone tumors</title><author>Nouri, H ; Hedi Meherzi, M ; Ouertatani, M ; Mestiri, M ; Zehi, K ; Douik, M ; Zouari, M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c454t-d11051e10e147a59d76baf9458d26a81160b2021c9e173e718ee06527a57e49e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Bone</topic><topic>Bone Density Conservation Agents - therapeutic use</topic><topic>Bone Neoplasms - prevention & control</topic><topic>Bone Neoplasms - surgery</topic><topic>Calcitonin</topic><topic>Calcitonin - therapeutic use</topic><topic>Chemotherapy, Adjuvant</topic><topic>Curettage</topic><topic>Female</topic><topic>Giant cell tumor</topic><topic>Giant Cell Tumor of Bone - prevention & control</topic><topic>Giant Cell Tumor of Bone - surgery</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neoplasm Recurrence, Local - prevention & control</topic><topic>Orthopedics</topic><topic>Retrospective Studies</topic><topic>Surgery</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nouri, H</creatorcontrib><creatorcontrib>Hedi Meherzi, M</creatorcontrib><creatorcontrib>Ouertatani, M</creatorcontrib><creatorcontrib>Mestiri, M</creatorcontrib><creatorcontrib>Zehi, K</creatorcontrib><creatorcontrib>Douik, M</creatorcontrib><creatorcontrib>Zouari, M</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Orthopaedics & traumatology, surgery & research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nouri, H</au><au>Hedi Meherzi, M</au><au>Ouertatani, M</au><au>Mestiri, M</au><au>Zehi, K</au><au>Douik, M</au><au>Zouari, M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Calcitonin use in giant cell bone tumors</atitle><jtitle>Orthopaedics & traumatology, surgery & research</jtitle><addtitle>Orthop Traumatol Surg Res</addtitle><date>2011-09-01</date><risdate>2011</risdate><volume>97</volume><issue>5</issue><spage>520</spage><epage>526</epage><pages>520-526</pages><issn>1877-0568</issn><eissn>1877-0568</eissn><abstract>Summary Introduction As osteoclast, giant cell tumors express calcitonin receptors. The aim of this paper is to assess treatment using salmon calcitonin after curettage. Material and methods We retrospectively reviewed 25 patients with giant cell tumor of the appendicular skeleton treated with a single protocol of calcitonin administration following curettage in order to assess the effectiveness of calcitonin in reducing the rate of local recurrence. Results The mean duration follow-up was 68 months. Thirteen patients (52%) had local recurrence. Eight of them were treated successfully after repeated curettage and calcitonin. Four patients had bone resection and one patient had curettage and cement filling. All patients with cavity left empty had ossified and the functional score as assessed by the MSTS score was 28.02/30. Conclusion This study suggests that the use of calcitonin as adjuvant is not effective and that filling agents are not required after curettage of giant cell tumors. Level of evidence Level 4.</abstract><cop>France</cop><pub>Elsevier Masson SAS</pub><pmid>21723215</pmid><doi>10.1016/j.otsr.2011.03.019</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1877-0568 |
| ispartof | Orthopaedics & traumatology, surgery & research, 2011-09, Vol.97 (5), p.520-526 |
| issn | 1877-0568 1877-0568 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_887503575 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; ScienceDirect Journals (5 years ago - present) |
| subjects | Adolescent Adult Aged Bone Bone Density Conservation Agents - therapeutic use Bone Neoplasms - prevention & control Bone Neoplasms - surgery Calcitonin Calcitonin - therapeutic use Chemotherapy, Adjuvant Curettage Female Giant cell tumor Giant Cell Tumor of Bone - prevention & control Giant Cell Tumor of Bone - surgery Humans Male Middle Aged Neoplasm Recurrence, Local - prevention & control Orthopedics Retrospective Studies Surgery Young Adult |
| title | Calcitonin use in giant cell bone tumors |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T08%3A48%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Calcitonin%20use%20in%20giant%20cell%20bone%20tumors&rft.jtitle=Orthopaedics%20&%20traumatology,%20surgery%20&%20research&rft.au=Nouri,%20H&rft.date=2011-09-01&rft.volume=97&rft.issue=5&rft.spage=520&rft.epage=526&rft.pages=520-526&rft.issn=1877-0568&rft.eissn=1877-0568&rft_id=info:doi/10.1016/j.otsr.2011.03.019&rft_dat=%3Cproquest_cross%3E887503575%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=887503575&rft_id=info:pmid/21723215&rft_els_id=1_s2_0_S1877056811001277&rfr_iscdi=true |